Barclays analyst Carter Gould keeps an Overweight rating on AbbVie (ABBV) after the company disclosed that both of its registrational studies of emraclidine for schizophrenia failed to meet their ...
Edgewater Research contended in a note to investors earlier this morning that performance issues with Monolithic Power’s (MPWR) voltage regulator module/Power Management IC “appear likely to severely ...